BetaInsiders sold $35.6M in the past 12 months.98% was sold under disclosed trading plans, 2% to cover taxes. The largest seller, Lawrence Klein (Chief Executive Officer, Director), sold $9.4M. 75% of these sales were shares from exercising options.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
A share of stake is shown for 0 of the 6 officers and directors who sold. 11 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Lawrence Klein, Laura Sandler, Cameron Turtle, Arjun Agarwal, Joana Goncalves, Paul Quinlan, Kristine Ball, Carl Dambkowski, Samarth Kulkarni, Christopher Martin and Larry Edwards (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Lawrence Klein Chief Executive Officer, Director | 25,000 | $83.62 | n/a | n/a | Oct 1, 2026 | Oct 2, 2026 |
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Paul Quinlan General Counsel | 10,000 | $93.64 | n/a | n/a | Sep 21, 2026 | Sep 21, 2026 |
| Arjun Agarwal Senior Vice President, Finance | 533 | $95.75 | n/a | n/a | Sep 21, 2026 | Sep 21, 2026 |
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Joana Goncalves Chief Medical Officer | 7,000 | $91.93 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Lawrence Klein Chief Executive Officer, Director | 2,452 | $95.71 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
| Paul Quinlan General Counsel | 1,039 | $95.71 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
| Joana Goncalves Chief Medical Officer Also under a disclosed plan | 947 | $95.71 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
| Laura Sandler Chief Operating Officer | 906 | $95.71 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
| Arjun Agarwal Senior Vice President, Finance Also under a disclosed plan | 560 | $95.71 | n/a | n/a | Sep 15, 2026 | Sep 15, 2026 |
"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.
Fairmount Funds Management LLC sold $300M in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.
Yes. Lawrence Klein sold 106K shares ($9.4M) in the past 12 months, 95% of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 98% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 2% were to cover taxes. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Lawrence Klein Chief Executive Officer, Director | $9.4M 106K shares | Not confirmedshare of stake is being verified. Why | 95% under a disclosed plan, 5% to cover taxes |
| Carl Dambkowski Director | $8.6M 140K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Paul Quinlan General Counsel | $6.8M 65K shares | Not confirmedshare of stake is being verified. Why | 97% under a disclosed plan, 3% to cover taxes |
| Joana Goncalves Chief Medical Officer | $4.5M 73K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Arjun Agarwal Senior Vice President, Finance | $4.3M 53K shares | Not confirmedshare of stake is being verified. Why | 99.6% under a disclosed plan, 0.4% to cover taxes |
| Laura Sandler Chief Operating Officer | $1.9M 35K shares | Not confirmedshare of stake is being verified. Why | 92% under a disclosed plan, 8% to cover taxes |
Outside holder, reported separately: Fairmount Funds Management LLC (a 10% owner, not part of management). Sold $300M (3.55M shares) from Jul 1, 2026 to Jul 1, 2026. Latest filing
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lawrence Klein!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Lawrence Klein are complete. Chief Executive Officer, Director | n/a | −106K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Lawrence KleinHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Lawrence Klein are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Laura Sandler!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Laura Sandler are complete. Chief Operating Officer | n/a | −35K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Laura SandlerHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Laura Sandler are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Cameron Turtle!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Cameron Turtle are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Cameron TurtleHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Cameron Turtle are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Arjun Agarwal!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Arjun Agarwal are complete. Senior Vice President, Finance | n/a | −53K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Arjun AgarwalHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Arjun Agarwal are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Joana Goncalves!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Joana Goncalves are complete. Chief Medical Officer | n/a | −73K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Joana GoncalvesHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joana Goncalves are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Paul Quinlan!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Paul Quinlan are complete. General Counsel | n/a | −65K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Paul QuinlanHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Paul Quinlan are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Kristine Ball!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kristine Ball are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Kristine BallHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kristine Ball are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Carl Dambkowski!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carl Dambkowski are complete. Director | n/a | −140K | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Carl DambkowskiHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Dambkowski are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Samarth Kulkarni!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Samarth Kulkarni are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Samarth KulkarniHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Samarth Kulkarni are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Christopher Martin!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Martin are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Christopher MartinHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Martin are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Larry Edwards!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Larry Edwards are complete. Chief Commercial Officer | n/a | 0 | n/a | n/a | ||||||||||||||||||||||||
Vesting, gifts, unvested awards and holding lines for Larry EdwardsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Larry Edwards are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($84.78 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close. | ||||||||||||||||||||||||||||
Holdings and share of stake for Oruka Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $35.6M across 470,733 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($777K), including tax-related sales outside a plan.
$1.0M of sales (2.9%) cite tax obligations in their footnotes, $264K of them also under a plan. Example: Paul Quinlan, Sep 15, 2026
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Lawrence Klein Chief Executive Officer, Director | 106K | $9.4M | 95% | 26% | Mar 16, 2026 to Oct 1, 2026 |
| Carl Dambkowski Director | 140K | $8.6M | 100% | 24% | May 21, 2026 to Jun 12, 2026 |
| Paul Quinlan General Counsel | 65K | $6.8M | 97% | 19% | Mar 16, 2026 to Sep 21, 2026 |
| Joana Goncalves Chief Medical Officer | 73K | $4.5M | 100% | 13% | Dec 19, 2025 to Sep 15, 2026 |
| Arjun Agarwal Senior Vice President, Finance | 53K | $4.3M | 99.6% | 12% | Mar 16, 2026 to Sep 21, 2026 |
| Laura Sandler Chief Operating Officer | 35K | $1.9M | 92% | 5% | Jan 2, 2026 to Sep 15, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $0 | $0 | $0 | $0 |
| Nov 2025 | $0 | $0 | $0 | $0 |
| Dec 2025 | $214K | $214K | $0 | $0 |
| Jan 2026 | $593K | $593K | $0 | $0 |
| Feb 2026 | $227K | $227K | $0 | $0 |
| Mar 2026 | $623K | $480K | $143K | $0 |
| Apr 2026 | $463K | $463K | $0 | $0 |
| May 2026 | $7.6M | $7.6M | $0 | $0 |
| Jun 2026 | $4.0M | $3.8M | $213K | $0 |
| Jul 2026 | $1.9M | $1.9M | $0 | $0 |
| Aug 2026 | $7.5M | $7.5M | $0 | $0 |
| Sep 2026 | $10.4M | $10.0M | $421K | $0 |
| Oct 2026 | $2.1M | $2.1M | $0 | $0 |
Unusual for this company: officers and directors sold shares for the first time in 6 years. 6 insiders sold; the average is 0 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 13, 2026 Latest 12 months | 471K | 6 | $35.6M |
| Oct 13, 2025 1 year earlier | 0 | 0 | $0 |
| Oct 13, 2024 2 years earlier | 0 | 0 | $0 |
| Oct 14, 2023 3 years earlier | 0 | 0 | $0 |
| Oct 14, 2022 4 years earlier | 0 | 0 | $0 |
| Oct 14, 2021 5 years earlier | 0 | 0 | $0 |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Oruka Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 452 Forms 3, 4 and 5 on record for Oruka Therapeutics, Inc. (SEC CIK 907654), filed from Mar 17, 2003 to Oct 2, 2026; 54 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages. 1 older filing exists only on paper and could not be read.
Probable 1-for-6 stock split on or before Mar 4, 2013 (split date stated in a footnote). Splits aren't reported as transactions; 6 holding lines changed by exactly this ratio, so earlier share counts are restated.
Probable 1-for-7 stock split on or before Sep 18, 2015 (first filing that shows post-split balances). Splits aren't reported as transactions; 5 holding lines changed by exactly this ratio, so earlier share counts are restated.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| VENROCK HEALTHCARE CAPITAL PARTNERS LP | Feb 27, 2025 | 4,148,428 shares, last reported balance as of Feb 14, 2025 |
| Funicular Fund, LP | Aug 30, 2024 | 9,161,356 shares, last reported balance as of Dec 16, 2022 |
| JANUS HENDERSON GROUP PLC | Aug 20, 2024 | 2,117,213 shares, last reported balance as of Aug 16, 2024 |
| Linda Grais | Jan 31, 2024 | 11,712 shares, last reported balance as of Mar 29, 2010 |
| Raymond Woosley | Jan 31, 2024 | No balance on record |
| Robert Conway | Jan 31, 2024 | 50,000 shares, last reported balance as of Jan 30, 2024 |
| Daniel Mitchell | Jan 31, 2024 | 611 shares, last reported balance as of Jan 30, 2024 |
| Anders Hove | Jan 31, 2024 | 382,759 shares, last reported balance as of Feb 16, 2017 |
| James Flynn | Jan 31, 2024 | No balance on record |
| Anders Hove | Jan 31, 2024 | 1,158,572 shares, last reported balance as of Feb 16, 2017 |
| Thomas Keuer | Dec 9, 2022 | 39,523 shares, last reported balance as of Dec 8, 2022 |
| Jeffrey Dekker | Dec 9, 2022 | 40,000 shares, last reported balance as of Dec 8, 2022 |
| Michael Bristow | Dec 16, 2021 | 4,808 shares, last reported balance as of Dec 14, 2021 |
| Christopher Ozeroff | Dec 16, 2021 | 48,603 shares, last reported balance as of Dec 14, 2021 |
| Brian Selby | Dec 23, 2020 | No balance on record |
| Growth Equity Opportunities IV, LLC | Feb 27, 2018 | No balance on record |
| Peter Sonsini | Feb 27, 2018 | No balance on record |
| Jon Sakoda | Feb 27, 2018 | No balance on record |
| Joshua Makower | Feb 27, 2018 | No balance on record |
| Ravi Viswanathan | Feb 27, 2018 | No balance on record |
| Scott Sandell | Feb 27, 2018 | No balance on record |
| Anthony Florence Jr. | Feb 27, 2018 | No balance on record |
| David Mott | Feb 27, 2018 | No balance on record |
| Forest Baskett | Feb 27, 2018 | No balance on record |
| Peter Barris | Feb 27, 2018 | No balance on record |
| Harry Weller | Jun 17, 2015 | 1,460,209 shares, last reported balance as of Jun 16, 2015 |
| Krishna Kolluri | Jun 17, 2015 | 1,460,209 shares, last reported balance as of Jun 16, 2015 |
| riley mccormack | Jan 16, 2015 | 917,857 shares, last reported balance as of Jan 16, 2015 |
| Patrick Wheeler | Sep 19, 2014 | 2,473 shares, last reported balance as of Sep 18, 2014 |
| John Zabriskie | Sep 19, 2013 | 3,717 shares, last reported balance as of Oct 22, 2012 |
| Atlas Venture Fund VII L P | Nov 2, 2012 | 37,608 shares, last reported balance as of Oct 25, 2012 |
| Jean Formela | Oct 24, 2012 | No balance on record |
| Jean Formela | Oct 24, 2012 | 69,456 shares, last reported balance as of Oct 22, 2012 |
| Burton Sobel | Feb 14, 2012 | No balance on record |
| Richard Brewer | Feb 14, 2012 | 1,988 shares, last reported balance as of Jan 27, 2009 |
| Ted Love | Feb 9, 2010 | 759 shares, last reported balance as of May 30, 2008 |
| Mary Pendergast | Feb 9, 2010 | 48 shares, last reported balance as of Dec 22, 2003 |
| William Freytag | Feb 9, 2010 | No balance on record |
| David Lowe | Jul 22, 2009 | No balance on record |
| David Lowe | Jul 22, 2009 | 3,086 shares, last reported balance as of Jul 21, 2009 |
| Kathryn Falberg | Jun 26, 2009 | No balance on record |
| Skyline Venture Partners Qualified Purchaser Fund IV L P | Jun 15, 2009 | 7,986 shares, last reported balance as of Jun 15, 2009 |
| BOULDER VENTURES IV ANNEX LP | Apr 8, 2009 | 17,159 shares, last reported balance as of Apr 6, 2009 |
| Lee Bendekgey | Feb 17, 2009 | 191 shares, last reported balance as of Nov 28, 2008 |
| Randall St Laurent | Feb 5, 2009 | No balance on record |
| Mark Perry | Jun 5, 2008 | 1,567 shares, last reported balance as of Sep 28, 2006 |
| Kimberly Popovits | Jun 5, 2008 | No balance on record |
| James Gavin III | Jun 4, 2008 | 595 shares, last reported balance as of May 24, 2006 |
| Michael Levy | Feb 4, 2008 | 710 shares, last reported balance as of Aug 31, 2007 |
| Barry Zubrow | Jun 1, 2007 | 1,190 shares, last reported balance as of Feb 20, 2004 |
| Henry Wolff | Feb 2, 2007 | 5 shares, last reported balance as of Nov 30, 2006 |
| Gary Titus | Aug 31, 2006 | 125 shares, last reported balance as of Aug 30, 2006 |
| George Rathmann | May 26, 2005 | 21,543 shares, last reported balance as of Dec 30, 2004 |
| Suisse Credit | Sep 2, 2004 | 137,312 shares, last reported balance as of Jul 30, 2004 |
| Linda Fitzpatrick | Jun 1, 2004 | No balance on record |
| Peter Garcia | Jun 1, 2004 | No balance on record |
| Philippe Chambon | May 10, 2004 | No balance on record |
| Philippe Chambon | May 10, 2004 | 137,140 shares, last reported balance as of Dec 3, 2003 |
| Carter Mc III | Oct 16, 2003 | No balance on record |
| Martin Vogelbaum | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.